Company Overview and News

 
4 Solid Insurance Stock Picks: Can These Continue the Bull Run?

2018-04-06 investorplace
As the year 2018 set in, the insurance industry started to witness the wheel of fortune turning in its favor with the rising interest rates, improving economy, lower-than-expected catastrophe loss (as compared to 2017, which emerged as the costliest year in terms of cat loss) as well as a noteworthy tax reform effective Jan 1, 2018.
Upvote Downvote

 
New Strong Buy Stocks for March 7th

2018-03-07 investorplace
Abercrombie & Fitch Co. (NYSE:ANF): This specialty retailer has seen the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
Upvote Downvote

1
AEL / American Equity Investment Life Holding Co. 10-K (Annual Report)

2018-02-23 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
americanequityinvestmentlife.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 7 )*       Name of issuer:  American Equity Investment Life Holding Co     Title of Class of Securities:  Common Stock     CUSIP Number:  025676206     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to whi
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-14 sec.gov
americanequityinvestmentlife.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 7 )*       Name of issuer:  American Equity Investment Life Holding Co     Title of Class of Securities:  Common Stock     CUSIP Number:  025676206     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to whi
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 10)*       AMERICAN EQUITY INVT LIFE HL (Name of Issuer)   Common Stock (Title of Class of Securities)     025676206                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 10)*       AMERICAN EQUITY INVT LIFE HL (Name of Issuer)   Common Stock (Title of Class of Securities)     025676206                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this
Upvote Downvote

 
American Equity Investment Life Holding's (AEL) CEO John Matovina on Q4 2017 Results - Earnings Call Transcript

2018-02-08 seekingalpha
American Equity Investment Life Holding Company (NYSE:AEL) Q4 2017 Earnings Conference Call February 8, 2018 10:00 AM ET
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. 8-K (Current Report)

2018-02-07 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2018 AMERICAN EQUITY INVESTMENT LIFE HOLDING COMPANY (Exact Name of Registrant as Specified in its Charter) Iowa 001-31911 42-1447959 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-23 fintel.io
American Equity Investment Life Holding Co. (NYSE:AEL) has 238 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 86,075,775 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., Dimensional Fund Advisors Lp, Macquarie Group Ltd, Apollo Management Holdings, L.P., Earnest Partners Llc, State Street Corp, Ameriprise Financial Inc, Snow Capital Management Lp, and Invesco Ltd.
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us0256762065_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) AMERICAN EQUITY INVESTMENT LIFE HOLDING COMPANY -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 025676206 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------
Upvote Downvote

 
AEL / American Equity Investment Life Holding Co. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us0256762065_012318.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) AMERICAN EQUITY INVESTMENT LIFE HOLDING COMPANY -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 025676206 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------
Upvote Downvote

1
Top Ranked Value Stocks to Buy for December 13th

2017-12-14 investorplace
Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 13th:
Upvote Downvote

 
Torchmark (TMK) Looks Promising: Time to Add the Stock?

2017-11-27 zacks
Torchmark Corporation’s (TMK - Free Report) niche market focus, solid operating fundamentals and a prudent capital management position it well for growth. The company has been witnessing positive estimate revisions over the past 60 days. This Zacks Rank #2 (Buy) life insurer remains promising on the back of a number of growth drivers. Northbound Estimates: The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 1.
Upvote Downvote

 
Here's Why You Should Buy Reinsurance Group (RGA) for Now

2017-11-23 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) remains well poised for growth, banking on changing life reinsurance pricing environment and expanding business in the pension risk transfer market. The Zacks Rank #2 (Buy) life insurer holds immense potential owing to a few good growth drivers. Growth Projections: The stock has seen the Zacks Consensus Estimate for current-year earnings per share being pegged at $11.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 025676206